GoKawiilEfferon's pediatric sepsis blood filter wins CE mark, eyes FDA filing
Startup Efferon has developed a blood-purification device called Efferon NEO that absorbs both endotoxins and cytokines to treat pediatric sepsis, which kills about 3 million children under five each year. The device received CE mark approval in April, making it the first multimodal blood purification device built specifically for children, and is now used in ICUs across 30 countries including parts of Europe, Saudi Arabia, and Thailand. Efferon is preparing an FDA submission and expects to reach $2 million in annualized revenue by the end of 2026.
GoKawiil's interpretation of the reporting above, not reported fact.
Pediatric medical devices are often adapted from adult versions rather than purpose-built, so a device engineered for children's lower blood volume could address a gap in sepsis treatment for younger patients. The company's selection for TechCrunch Disrupt's Startup Battlefield suggests it is seeking visibility and investment as it pursues FDA clearance, a step that would open the US market. Its international ICU adoption ahead of FDA approval indicates regulatory pathways outside the US may be enabling earlier real-world use.
- Efferon NEO is a CE-marked device for treating pediatric sepsis by absorbing both endotoxins and cytokines from blood.
- The device is already deployed in ICUs across 30 countries and the company is preparing for FDA approval.
- Efferon projects $2 million in annualized revenue by the end of 2026, with roots in research from Moscow State University.
Source: techcrunch.com — Marina Temkin, 2026-10-11
Published there as: “Efferon wants to eradicate the devastating toll of pediatric sepsis”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.